Infection episodes and islet autoantibodies in children at increased risk for type 1 diabetes before and during the COVID-19 pandemic

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • for the GPPAD Study Group - (Author)
  • Ivo Zeller - , Helmholtz Zentrum München - German Research Center for Environmental Health (Author)
  • Andreas Weiss - , Helmholtz Zentrum München - German Research Center for Environmental Health (Author)
  • Stefanie Arnolds - , Helmholtz Zentrum München - German Research Center for Environmental Health (Author)
  • Katharina Schütte-Borkovec - , Helmholtz Zentrum München - German Research Center for Environmental Health (Author)
  • Sari Arabi - , Center for Regenerative Therapies Dresden, Department of Paediatrics, University Hospital Carl Gustav Carus Dresden (Author)
  • Thekla von dem Berge - , Children's Hospital Auf der Bult (Author)
  • Kristina Casteels - , KU Leuven (Author)
  • Angela Hommel - , Chair of Preclinical stem cell therapy and diabetes (Author)
  • Olga Kordonouri - , Children's Hospital Auf der Bult (Author)
  • Helena Elding Larsson - , Lund University (Author)
  • Markus Lundgren - , Lund University, Kristianstad Hospital (Author)
  • Anne Rochtus - , KU Leuven (Author)
  • Matthew D. Snape - , University of Oxford (Author)
  • Agnieszka Szypowka - , Medical University of Warsaw (Author)
  • Manu Vatish - , University of Oxford (Author)
  • Christiane Winkler - , Helmholtz Zentrum München - German Research Center for Environmental Health (Author)
  • Ezio Bonifacio - , Chair of Preclinical stem cell therapy and diabetes, German Center for Diabetes Research - Paul Langerhans Insitute Dresden (Partner: HMGU), University Hospital Carl Gustav Carus Dresden (Author)
  • Anette Gabriele Ziegler - , Helmholtz Zentrum München - German Research Center for Environmental Health, Technical University of Munich (Author)

Abstract

Objectives: To determine the impact of the COVID-19 pandemic on the incidence rates of infection and islet autoimmunity in children at risk for type 1 diabetes. Methods: 1050 children aged 4 to 7 months with an elevated genetic risk for type 1 diabetes were recruited from Germany, Poland, Sweden, Belgium and the UK. Reported infection episodes and islet autoantibody development were monitored until age 40 months from February 2018 to February 2023. Results: The overall infection rate was 311 (95% Confidence Interval [CI], 304–318) per 100 person years. Infection rates differed by age, country, family history of type 1 diabetes, and period relative to the pandemic. Total infection rates were 321 per 100 person-years (95% CI 304–338) in the pre-pandemic period (until February 2020), 160 (95% CI 148–173) per 100 person-years in the first pandemic year (March 2020—February 2021; P < 0.001) and 337 (95% CI 315–363) per 100 person-years in subsequent years. Similar trends were observed for respiratory and gastrointestinal infections. Islet autoantibody incidence rates were 1.6 (95% CI 1.0–2.4) per 100 person-years in the pre-pandemic period, 1.2 (95% CI 0.8–1.9) per 100 person-years in the first pandemic year (P = 0.46), and 3.4 (95% CI 2.3–4.8) per 100 person-years in subsequent years (P = 0.005 vs. pre-pandemic year; P < 0.001 vs. first pandemic year). Conclusions: The COVID-19 pandemic was associated with significantly altered infection patterns. Islet autoantibody incidence rates increased two-fold when infection rates returned to pre-pandemic levels.

Details

Original languageEnglish
Article number e1004107
Pages (from-to)2465-2473
Number of pages9
JournalInfection
Volume52 (2024)
Issue number6
Publication statusPublished - 14 Jun 2024
Peer-reviewedYes

External IDs

PubMed 38874748
ORCID /0000-0002-8704-4713/work/173988536

Keywords

Sustainable Development Goals

Keywords

  • Autoimmunity, COVID-19, Infection, Type 1 diabetes